Evolent's 'Auth Intelligence' Tipping Point Turns a 90-Day Rally Into a Comeback Narrative

A specialty-care manager crushed by a -88% drawdown raises guidance, guides to >25% 2027 growth and a $150M EBITDA step-up — with a company-unique AI automation story driving the turn.

EVH · Earnings Call · 2026-08-06

The turn after the fall

Evolent Health has spent three years in an extraordinary drawdown — the stock is down roughly 75% since 2015 and still sits about 88% below its September 2022 peak, with price-to-revenue crushed to 0.1x. But the tape has flipped hard: over the last 90 trading days EVH is up more than 100%, and the Q2 report delivered August 6 gives the rally a fundamental reason to exist. Revenue came in at $653 million, up 31% sequentially; adjusted EBITDA of $28 million rose 27% qoq; and management raised full-year revenue guidance to $2.6–2.7 billion while tightening adjusted EBITDA to $120–135 million. Seth Blackley opened by framing the quarter as proof the model is working: “Today, we reported a strong second quarter with results that reflect our continued ability to execute on our commitments.” — Seth Blackley, Chief Executive Officer · 2026-08-06 The sequential revenue jump is essentially the launch of Highmark on May 1, which pushed the medical expense ratio (MER) to 95% and is the reason Q2's beat carried a timing flavor — prior-year development was pulled forward from Q3. Mario Ramos was explicit that the reserving posture on new contracts stays conservative, and that Q3's expected sequential EBITDA gain is now more modest as a result. Revenue momentum: from $496M (latest filed Q1) to $653M in Q2, with FY guidance raised to $2.6–2.7B.

Auth Intelligence becomes the narrative

The genuinely new thing on this call — company-unique, not sector boilerplate — is Auth Intelligence, the prior-authorization AI engine built on the 2024 Machinify acquisition. It is the #1 keyword in the company's own trajectory (momentum 194 this quarter vs 69 a quarter ago), and management made it the centerpiece of the 2027 margin story.

We believe Q2 is a tipping point in our AI journey as we saw these efforts take root and accelerate past the pilot phases and to a point of meaningful scale with a clear line of sight to more.
Seth Blackley, Chief Executive Officer · 2026-08-06

The proof points are specific: auto approval rate improvements of up to 20 percentage points (55% → 75%) with no clinical degradation, and more than a third of previously-manual authorization volume now flowing through the platform. This is a sharper, more measurable claim than the prior AI positioning — on last quarter's call Seth described the business as a “tale of 2 cities” — Seth Blackley, Chief Executive Officer · 2026-05-07, where most growth is in oncology but roughly 95% of approval volume is elsewhere. Now that "where" has a number attached to it.

2027: growth over 25%, EBITDA $150M+, and a refilled pipeline

The second big change is the 2027 outlook. Mario's framing was unhedged: “we expect revenue growth of more than 25% in 2027... the midpoint of our 2027 adjusted EBITDA outlook is expected to be at or above $150 million” — Mario Ramos, Chief Financial Officer · 2026-08-06. That is a genuine earnings inflection after years of negative operating income — the latest filed quarter shows -$26M, and Q4 2025 closed at a -$431M operating loss. Growth comes from two deals announced the same morning: an oncology Performance Suite expansion with an existing advanced imaging client (~1.5M Medicaid + Medicare lives across 11 states, ~$300M in annualized revenue expected by December), and a former NIA regional Blue plan broadening its specialty platform. Seth on the pipeline: “The pipeline has refilled... a couple of the top 10 plans in the country that we don't yet have... are now in the pipeline” — Seth Blackley, Chief Executive Officer · 2026-08-06. The EBITDA growth rests on Performance Suite margin maturation plus the AI cost takeouts. Price-to-revenue remains near a decade low despite the raise.

The caveats: membership, net debt, and reserving conservatism

It is not clean escape velocity. Mario quantified the backdrop — a ~20% decline in Medicaid expansion members translates to 4–5% membership loss for EVH, plus exchange and client-specific attrition — the membership decline theme that has dogged the name since 2025. Net debt sat at $808M with 2029 maturities; management promised “a clear path to significantly improving our leverage ratios and our maturity profile within the next 12 to 24 months.” It all hangs on reserving discipline. Mario said last quarter: “when we have new contracts, we do reserve, and we have a different level of reserves and ongoing business” — Mario Ramos, Chief Financial Officer · 2026-02-25. That same conservatism is what makes the $150M target credible — but it also means Q2's beat carried a timing component. At 0.1x price-to-revenue, the market still prices this as a distressed asset; the 90-day rally may just be starting to reflect what the guidance says.